跳至主要内容
临床试验/NCT05464316
NCT05464316招募中不适用

Comparing the Effectiveness of the Adjustable Trans Obutator Male System (ATOMS) Versus the Artificial Urinary Sphincter (AUS) in Moderate to Severe Post-Prostatectomy Stress Urinary Incontinence

Université de Sherbrooke2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年1月13日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
60
试验地点
2
主要终点
To compare effectiveness of the ATOMS and AUS devices in patients using results from the 24-hour pad test.

研究概览

简要总结

Post-Prostatectomy Incontinence (PPI) is a common complication affecting 1% to 40% of patients after surgery. When conservative treatments fail, the installation of an artificial urinary sphincter (AUS) has been the treatment of choice for PPI since its introduction more than 50 years ago. Although small studies suggest inferior success rate of male slings compare to the AUS in moderate to severe male incontinence; recent studies, one prospective and one Canadian multicenter cohort study, have demonstrated adjustable transobturator male sling (ATOMS) as a safe and efficient alternative to treat PPI. Interestingly, the ATOMS does not required any operation manipulation from the user in order to void and it causes potentially less urethral erosion and less urethral atrophy than the AUS; although those findings were never compared head to head with the AUS. Therefore, we believe that a thorough prospective non-inferiority study comparing the outcomes and effectiveness of the ATOMS device versus the AUS in treating moderate to severe PPI could prove itself useful in guiding urologists and patients to choose their best treatment of male incontinence. The null hypothesis posed for the present study is that ATOMS is non inferior to AUS for the treatment of moderate to severe PPI using the non-inferiority margin of 15% to be of acceptable lower effectiveness.

With regards to study methods, this will be a pilot prospective, randomized controlled trial, non-blinded with a non-inferiority design. This pilot study will take place at the CIUSSS de l'Estrie, in Sherbrooke, Quebec, Canada, with two surgeons. All male patients with moderate to severe incontinence after their prostate surgery, who are suitable for incontinence surgery will be screened for study eligibility respecting the exclusion and inclusion criteria. After written informed consent, enrolled patients will be randomized assigned (1:1) to one of the two interventions' arms (AUS or ATOMS). Sixty patients are estimated to be randomized in the two arms the day of their surgery with a computer-based algorithm sequence.

By completing this pilot prospective study, we hope to provide concrete and scientifically significant evidence on the effectiveness of ATOMS in the treatment of moderate to severe PPI comparing with the AUS. Although both treatments are commonly used today, there has been little evidence comparing both devices side by side with more severe PPI. We therefore hope to make a global impact with said project.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Adult men (≥ 18 years of age) with moderate-to-severe post-prostatectomy urinary incontinence who are eligible and have consented to receive surgery as treatment. Determining patient eligibility for surgery is based on the AUA/SUFU Guidelines, published in
  • Patients who consented to being randomised in receiving ATOMS and AUS.

排除标准

  • Patients whom the physician determines to be poor candidates for surgical procedures and/or anesthesia due to; poor manual dexterity, poor cognitive function, and other physical or mental conditions.
  • Patients who have unresolved urethral or urethral-vesical anastomose stenosis within the last 12 months.
  • Patients who have undergone previous incontinence surgeries.
  • Patients who suffer mild incontinence (less than 200g per day).
  • Patients with primarily neurogenic incontinence.
  • Patients with rising PSA levels within the previous 12 months.
  • Patients with urinary incontinence due to or complicated by an irreversibly obstructed lower urinary tract"
  • Patients with known allergies or sensitivity to rifampin or to minocycline HCl or other tetracyclines.", in InhibiZone implantation.

结局指标

主要结局

To compare effectiveness of the ATOMS and AUS devices in patients using results from the 24-hour pad test.

时间窗: Three years

To compare effectiveness of the ATOMS and AUS devices in patients using results from the Patient Global Impression of Improvement (PGI-I) questionnaire.

时间窗: Three years

次要结局

  • To compare complication rates of the AUS and ATOMS using the Clavien-Dindo Classification.(Three years)
  • To assess the impact of OAB and radiotherapy on the effectiveness of AUS and ATOMS using results from the 24-hour pad test.(Three years)
  • To assess the impact of OAB and radiotherapy on the effectiveness of AUS and ATOMS using results from the ICIQ-UI SF questionnaire.(Three years)
  • To assess the impact of OAB and radiotherapy on the effectiveness of AUS and ATOMS using results from the IPSS-QoL questionnaire.(Three years)
  • To compare effectiveness of the AUS and ATOMS devices in patients using results from the ICIQ-OAB questionnaire.(Three years)
  • To compare effectiveness of the AUS and ATOMS devices in patients using results from the ICIQ-UI SF questionnaire.(Three years)
  • To compare effectiveness of the AUS and ATOMS devices in patients using results from the ICIQ-MLUTS LF questionnaire.(Three years)
  • To compare effectiveness of the AUS and ATOMS devices in patients using results from the IPSS-QoL questionnaire.(Three years)
  • To assess the impact of OAB and radiotherapy on the effectiveness of AUS and ATOMS using results from the Patient Global Impression of Improvement (PGI-I) questionnaire.(Three years)
  • To assess the impact of OAB and radiotherapy on the effectiveness of AUS and ATOMS using results from the ICIQ-MLUTS LF questionnaire.(Three years)
  • To assess the impact of OAB and radiotherapy on the effectiveness of AUS and ATOMS using results from the 24-hour pad-count.(Three years)
  • To compare effectiveness rates of the AUS and ATOMS using the results of the 24-hour pad-counts.(Three years)
  • To assess the impact of OAB and radiotherapy on the safety of AUS and ATOMS using Clavien-Dindo Classification to report adverse event frequency and severity.(Three years)
  • To assess the impact of OAB and radiotherapy on the effectiveness of AUS and ATOMS using results from the ICIQ-OAB questionnaire.(Three years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Le Mai Tu

Urologist, Professor

Université de Sherbrooke

研究点 (2)

Loading locations...

相似试验

Prospective Pilot ATOMS vs AUS | 临床试验